Bayer's new blood thinning drug passes safety tests
A new drug which has been manufactured by the German pharmaceutical company Bayer has proved to be just as successful as warfarin in preventing strokes.
The blood thinner Xarelto, which is also known as Rivaroxaban, has just undergone phase three clinical safety tests during a Japanese study.
The results of the study are being reported as positive, after it was found that it did not raise the risk of bleeding in Japanese stroke patients.
READ MORE FROM THE WDM CONTENT NETWORK:
To read the latest edition of Healthcare Global, click here
- Health concerns over Olympic McDonalds
- Scalpel treatment for Duchenne muscular dystrophy
- Tighter regulations proposed for animal testing in the UK
In a statement Bayer said of the results: "It is important that Rivaroxaban demonstrated non-inferior safety and that there were numerically fewer intracranial hemorrhages versus warfarin.”
The company has been seeking Japanese approval to market the Rivaroxaban drug for treating patients with irregular heartbeats since April.
Bayer believes potential sales of the blood thinning treatment could total US$2.3 billion each year, which is equivalent to €2 billion.
The drug was developed in partnership with Johnson & Johnson and it already sells in 110 countries across the world.
- Bayer to manufacture CureVac COVID-19 vaccineProcurement & Supply Chain
- Bayer announces rise in group sales for Q2 but warns of lower full-year earnings than expectedMedical Devices & Pharma
- Bayer Consumer Care AG licenses enterprise:inmation through its digital transformationTechnology & AI
- Bayer and Alibaba Health form new partnershipDigital Healthcare